• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

Blushwood Tree fruit kills some cancers in 48hrs

cancer berries australia

  • This topic is locked This topic is locked
34 replies to this topic

#31 jondoeuk

  • Registered User
  • 58 posts
  • 6
  • Location:UK
  • NO

Posted 01 June 2017 - 07:22 PM

Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas http://investors.adu...icle&ID=2278048

 

The company also plan to give an update on the Phase Ia which has now been completed http://investors.adu...icle&ID=2276846



#32 mag1

  • Registered User
  • 880 posts
  • 126
  • Location:virtual

Posted 01 June 2017 - 08:21 PM

Sorry.

 

PMID: 28342934



sponsored ad

  • Advert
To book this BIOSCIENCE ad spot and support Longecity (this will replace the google ad above) - click HERE.

#33 jondoeuk

  • Registered User
  • 58 posts
  • 6
  • Location:UK
  • NO

Posted 02 November 2017 - 03:37 AM

Data from a randomized, 26-patient, Phase 2 study evaluating G100, (novel, synthetic TLR4 agonist injected intratumorally), and low-dose radiation (XTR), versus G100 and XRT with the systemic administration of Merck's anti-PD-1 antibody, Keytruda (pembrolizumab) will be presented at ASH https://ash.confex.c...aper104167.html
 
 
The data in the submitted abstract show: A 31% ORR for patients receiving G100+XRT+pembrolizumab (G+P), as compared to a 15% ORR for patients receiving G100+XRT (G); and shrinkage of untreated (abscopal) tumours in 62% of patients receiving G+P and 46% of patients receiving G. These abstract data are earlier (June 2017) than the data that will be presented in the planned presentation. The updated data appear to demonstrate a stronger clinical response and biomarker profile for those patients receiving G100, XRT and pembrolizumab, as compared to those patients receiving G100 and XRT alone.


#34 jondoeuk

  • Registered User
  • 58 posts
  • 6
  • Location:UK
  • NO

Posted 14 November 2017 - 07:25 AM

Some posters from SITC

 

IMO-2125 (TLR9 agonist) will be ongoing into a PhIII next year for advanced melanoma patients who are refractory to PD(L)-1 blockade http://www.ideraphar...te-immunity.pdf

 

A PhI will happen using NKTR-262 (TLR 7/8 agonist) and they will then combine it with NKTR-214 (CD122-biased agonisthttp://www.nektar.co...er-P275.pdf.pdf

 

Another PhI will test ZVex-IL12 http://www.immunedes...12_v4_FINAL.pdf Immune Design who are behind that should also be testing the combo of G100 and CMB305 in subtypes of STS. In another poster they presented they showed the latter two have a synergist effect http://www.immunedesign.com/wp-content/uploads/2017/11/2017-SITC_Poster_GBM_v2_FINAL.pdf

 

Analyses of a PhII of pIL-12 plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1 http://oncosec.com/w...TER-2017_-1.pdf Depending on the outcome of the next trial then it could be approved early by the FDA.


Edited by jondoeuk, 14 November 2017 - 07:37 AM.


sponsored ad

  • Advert
To book this BIOSCIENCE ad spot and support Longecity (this will replace the google ad above) - click HERE.

#35 mag1

  • Registered User
  • 880 posts
  • 126
  • Location:virtual

Posted 14 November 2017 - 07:47 AM

Would NKTR214 combine well with alpha-c-galactosylceramide?

alpha-c-galactosylceramide turbo charges NK T cells because it fits right into their receptors.







Also tagged with one or more of these keywords: cancer, berries, australia

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users